aliskiren vs telmisartan
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of aliskiren and telmisartan. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
7 DRUG INTERACTIONS Aliskiren: Do not co-administer aliskiren with telmisartan in patients with diabetes. Avoid use of aliskiren with telmisartan in patients with renal impairment (GFR <60 mL/min). NSAIDs : Increased risk of renal impairment and loss of anti-hypertensive effect ( 7 ) Do not co-administer aliskiren with telmisartan in patients with diabetes ( 7 )
Tekturna
Micardis
Tekturna is a medicine used to treat high blood pressure. It helps lower blood pressure, which can reduce the risk of strokes and heart attacks.
Telmisartan (Micardis) is a medicine that lowers blood pressure. It belongs to a class of drugs called angiotensin II receptor blockers (ARBs).
Tekturna is used to treat high blood pressure in adults and children who weigh at least 110 pounds and are 6 years or older. Lowering your blood pressure helps prevent strokes and heart attacks. It is important to manage high blood pressure with a healthy lifestyle too.
Telmisartan is used to treat high blood pressure. Lowering blood pressure reduces the risk of strokes and heart attacks. It can also lower cardiovascular risk if you cannot take ACE inhibitors. Controlling high blood pressure is important for overall heart health.
Tekturna works by blocking a substance in your body called renin. Renin helps to control your blood pressure. By blocking renin, Tekturna helps to lower your blood pressure.
Telmisartan blocks a substance in your body that tightens blood vessels. This helps blood vessels relax and widens them. As a result, blood pressure is lowered.
- • Diarrhea
- • Back pain
- • Sinus infection
- • Diarrhea
- • Upper respiratory tract infection
- • Sore throat
- Asthenia 367
- Fall 356
- Nausea 336
- Dyspnoea 315
- Headache 301
- Nausea 2,059
- Fatigue 2,001
- Diarrhoea 1,794
- Dyspnoea 1,785
- Headache 1,715
Tekturna can harm your unborn baby, even causing death. If you become pregnant, stop taking Tekturna right away and tell your doctor.
If you are pregnant or plan to become pregnant, stop taking this medicine right away. Telmisartan can harm or cause death to your unborn baby.
Tekturna can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, talk to your doctor about other blood pressure medicines. Breastfeeding is not recommended while taking Tekturna.
Telmisartan can cause harm to your unborn baby, especially during the second and third trimesters. Do not breastfeed while taking telmisartan.
Also Compare, Nearby Drugs
Compare telmisartan with
How to Read This aliskiren vs telmisartan Comparison
aliskiren is classified in the Direct Renin Inhibitor drug class, while telmisartan sits within the Angiotensin II Receptor Blocker (ARB) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aliskiren has 1,675 submissions while telmisartan has 9,354. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to both of these medicines work on the same system to lower blood pressure, which can cause serious stress on the kidneys and high potassium levels.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aliskiren or telmisartan.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.